News|Videos|November 13, 2023
Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy
Author(s)Ritu Salani, MD, Bhavana Pothuri, MD
Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, discuss the prevalence of patients with recurrent endometrial cancer, challenges in responding to chemotherapy, and the potential for improved treatment options in the second-line setting.
Advertisement
Episodes in this series
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
4
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
5